Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
HIV infection highly increases the risk of progression of latent tuberculosis (TB) to active disease that therapy is recommended for all PPD-positive, HIV-infected patients, regardless of age. Sensitivity of the PPD testing is, however, dependent on a normal T cell function.
Therefore, an accurate and reliable method for detection of latent tuberculosis in patients with HIV is urgently needed.
This prospective study will examine the utility of interferon-gamma (IFN-γ) based assay, T-SPOT.TB,for detection of TB in HIV-infected individuals.
| Condition | Intervention |
|---|---|
| Latent Tuberculosis HIV Infections | Other: T-Spot.TB test |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV? |
| Enrollment: | 53 |
| Study Start Date: | May 2008 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| HIV infection |
Other: T-Spot.TB test
diagnostic test
|
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria
- adult individuals with confirmed HIV infection
Exclusion Criteria:
- Patients who are on INH treatment
- Patients who have a positive PPD test within 1 year of study enrollment
- Individuals with blistering or ulcerating skin disorder
- Pregnant women
- Patients who were given blood transfusion within 6 weeks prior to enrollment
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00763295
| United States, New York | |
| Staten Island University Hospital | |
| Staten Island, New York, United States, 10305 | |
More Information
| Responsible Party: | Jordan Glaser, MD, Staten Island University Hospital |
| ClinicalTrials.gov Identifier: | NCT00763295 History of Changes |
| Other Study ID Numbers: |
08-015 |
| First Submitted: | September 28, 2008 |
| First Posted: | September 30, 2008 |
| Last Update Posted: | October 26, 2012 |
| Last Verified: | October 2012 |
Keywords provided by Northwell Health:
|
latent tuberculosis HIV IFN-γ based assay |
Additional relevant MeSH terms:
|
HIV Infections Tuberculosis Latent Tuberculosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections |